文献速递前列腺癌

阿帕他胺联合雄激素剥夺治疗转移性去势敏感性前列腺癌:TITAN 3期研究中疼痛与疲劳分析

Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.
PubMed 文献 · J Urol · 2021-05-27

TITAN 3期随机双盲安慰剂对照试验的探索性分析,评估转移性去势敏感性前列腺癌患者接受阿帕他胺(240 mg/日)或安慰剂联合持续ADT的疼痛与疲劳报告结局。结果显示阿帕他胺组多项疼痛恶化时间显著延长,而疲劳变化两组相似。

要点

  • 阿帕他胺联合ADT较安慰剂延长多项疼痛恶化时间,疲劳无差异。
  • 疼痛干扰情绪和人际关系恶化时间不可估计(安慰剂组分别为22.4和23.0个月)。
  • 两组疲劳发生及恶化可能性相似,依从性高(96%-97%)。

核心结论

  • 转移性去势敏感性前列腺癌患者接受阿帕他胺联合ADT对比安慰剂联合ADT,报告一致的有利疼痛恶化时间。
  • 阿帕他胺与安慰剂相比未观察到疲劳变化的差异。

研究设计与样本

  • 3期随机双盲安慰剂对照TITAN试验(NCT02489318)的探索性分析。
  • 患者接受阿帕他胺240 mg/日或安慰剂,联合持续雄激素剥夺治疗。
  • 使用简明疼痛评估短表和简明疲劳量表评估患者报告结局。
  • 采用Kaplan-Meier法估计恶化时间,Cox比例风险模型计算风险比和95%置信区间。
  • 采用广义估计方程逻辑回归估计疼痛或疲劳恶化可能性的治疗差异。

主要发现

  • 第一年简明疼痛评估短表和简明疲劳量表完成依从性高(96%至97%)。
  • 中位随访时间两组相似(19至22个月)。
  • 阿帕他胺组中位疼痛恶化时间较安慰剂组长:过去24小时最轻疼痛(28.7 vs 21.8个月,p=0.0146)。
  • 疼痛干扰情绪(不可估计 vs 22.4个月,p=0.0017)、行走能力(28.7 vs 20.2个月,p=0.0027)、人际关系(不可估计 vs 23.0个月,p=0.0139)、睡眠(28.7 vs 20.9个月,p=0.0167)的恶化时间均延长。
  • 两组疲劳发生及疲劳恶化可能性相似。

关键数值与推荐

  • 阿帕他胺剂量为240 mg/日,联合持续ADT。
  • 疼痛恶化时间延长有统计学意义:最轻疼痛p=0.0146,干扰情绪p=0.0017,干扰行走p=0.0027,干扰关系p=0.0139,干扰睡眠p=0.0167。
  • 疲劳变化两组无显著差异(原文未报告具体数值)。

临床怎么用

  • 对于转移性去势敏感性前列腺癌患者,阿帕他胺联合ADT可能延缓疼痛恶化及相关干扰。
  • 治疗期间疲劳变化与安慰剂联合ADT相似,无需因疲劳差异调整治疗。

局限性

  • 为探索性分析,非主要终点。
  • 疼痛和疲劳为患者报告结局,可能存在报告偏倚。
  • 随访时间中位19至22个月,长期数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We performed an exploratory analysis of prostate cancer-related pain and fatigue on health-related quality of life in patients with metastatic castration-sensitive prostate cancer receiving apalutamide (240 mg/day) or placebo, with continuous androgen deprivation therapy (ADT), in the phase 3, randomized, double-blind, placebo controlled TITAN trial (NCT02489318). MATERIALS AND METHODS: Patient-reported outcomes for pain and fatigue were evaluated using the Brief Pain Inventory-Short Form and Brief Fatigue Inventory. Time to deterioration (TTD) was estimated by Kaplan-Meier method; hazard ratios and 95% confidence intervals were calculated using Cox proportional hazards model. General estimating equations for logistic regression estimated treatment-related differences in the likelihood of worsening pain or fatigue. RESULTS: Compliance for completing the Brief Pain Inventory-Short Form and Brief Fatigue Inventory was high (96% to 97%) in the first year. Median followup times were similar between treatments (19 to 22 months). Median pain TTD was longer with apalutamide than placebo for "pain at its least in the last 24 hours" (28.7 vs 21.8 months, respectively; p=0.0146), "pain interfered with mood" (not estimable vs 22.4 months; p=0.0017), "pain interfered with walking ability" (28.7 vs 20.2 months; p=0.0027), "pain interfered with relations" (not estimable vs 23.0 months; p=0.0139) and "pain interfered with sleep" (28.7 vs 20.9 months; p=0.0167). Likelihood for fatigue and worsening fatigue were similar between groups. CONCLUSIONS: Patients with metastatic castration-sensitive prostate cancer receiving apalutamide plus ADT vs placebo plus ADT reported consistently favorable TTD of pain. No difference for change in fatigue was observed with apalutamide vs placebo.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Agarwal N, McQuarrie K, Bjartell A, et al. Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study. J Urol. 2021. PMID: 34039013. doi:10.1097/JU.0000000000001841

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。